ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project
ProBioGen AG, a premier service & technology provider for complex therapeutic glycoproteins, today announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held…